Mesoblast Limited - American Depositary Shares (MESO) closed at $13.99 on November 10, 2026, down 3.1% from the previous close, on volume of 89,080 shares (30-day average 277,815).
Data as of November 10, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 14, 2026 | Diagonal Put Spread | 16-Oct-26 : 16-Apr-2714 : 13 P | 2,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
Globe Newswire (Wed, 4-Nov 7:11 PM ET)
Globe Newswire (Sun, 1-Nov 6:46 PM ET)
Market Chameleon (Thu, 29-Oct 4:32 AM ET)
Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)
Globe Newswire (Wed, 28-Oct 8:19 PM ET)
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
Globe Newswire (Thu, 24-Sep 7:00 AM ET)
Mesoblast Reports Substantial Revenue Growth to US$120M
Globe Newswire (Wed, 26-Aug 8:32 PM ET)
Mesoblast Financial Results and Corporate Update Webcast
Globe Newswire (Mon, 24-Aug 7:00 AM ET)
Globe Newswire (Sun, 16-Aug 8:35 PM ET)
Market Chameleon (Mon, 13-Apr 4:50 AM ET)
Strong Ryoncil® Performance Drives Revenue Gains and Expands Mesoblast's Growth Pipeline
Market Chameleon (Fri, 27-Feb 3:44 AM ET)
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Mesoblast Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol MESO.
As of November 10, 2026, MESO stock price declined to $13.99 with 89,080 million shares trading.
MESO has a beta of 1.79, meaning it tends to be more sensitive to market movements. MESO has a correlation of 0.16 to the broad based SPY ETF.
MESO has a market cap of $1.81 billion. This is considered a Small Cap stock.
Last quarter Mesoblast Limited - American Depositary Shares reported $120 million in Revenue and -$.04 earnings per share. This fell short of revenue expectation by $-61 million and exceeded earnings estimates by $.46.
In the last 3 years, MESO traded as high as $22.00 and as low as $1.61.
The top ETF exchange traded funds that MESO belongs to (by Net Assets): IBB, APIE, QQQS, IBBQ, BIB.
MESO has underperformed the market in the last year with a return of -4.2%, while the SPY ETF gained +12.9%. In the last 3 month period, MESO fell short of the market, returning -12.2%, while SPY returned -2.8%. However, in the most recent 2 weeks MESO has outperformed the stock market by returning +12.9%, while SPY returned -2.0%.
MESO support price is $13.85 and resistance is $15.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MESO shares will trade within this expected range on the day.
